Prostate-specific antigen (PSA) is a protein produced by prostate cells, and an elevated blood level can signal prostate cancer or other prostate conditions. The PSA blood test has been used for prostate cancer screening since the early 1990s and remains the most widely ordered prostate cancer screening test in the United States. Approximately 30 million PSA tests are performed in the U.S. each year. HCPCS code G0103 is the public-domain code that covers the prostate cancer screening PSA test billed to Medicare, payable under the Medicare Clinical Lab Fee Schedule. For CPT-coded diagnostic PSA tests ordered outside of the screening context, a different CPT code applies but is AMA-licensed and not reproduced here.
The U.S. Preventive Services Task Force (USPSTF) assigns a Grade C recommendation to PSA-based prostate cancer screening for men ages 55 to 69, meaning clinicians should offer the test only after an individualized discussion of benefits and harms. For men 70 and older, USPSTF recommends against routine screening (Grade D). The American Urological Association (AUA) and Society of Urologic Oncology (SUO) 2026 guideline takes a somewhat broader view, recommending shared decision-making starting at age 40 for men at average risk and earlier for high-risk groups (Black men, those with a first-degree relative diagnosed before age 65). Because the USPSTF grade is C rather than A or B, ACA-compliant plans are not required to cover the PSA test at 100%, though many cover it as a preventive benefit. Uninsured men and those on high-deductible health plans often pay the full cash price, which varies widely by site of service. Patients who qualify for Medicaid may receive the PSA test at no cost.
For uninsured men, the cash price varies more by site of service than by any other factor. A PSA test ordered through a direct-to-consumer lab service such as Quest Diagnostics or LabCorp costs $30 to $80 in 2026 for the lab component. The same test ordered in a physician office typically adds a visit fee and interpretation charge, bringing the total to $100 to $250. When the order originates in a hospital outpatient department, a facility fee applies and can push the total to $200 to $350 or more. This guide covers those pricing differences, what Medicare pays, how the No Surprises Act and the Good Faith Estimate requirement protect self-pay patients, and how to get the lowest available cash price.
PSA Test Cost by Site of Service in 2026
The biggest cost driver of PSA Test is the site of service: where the procedure is performed. 2026 CMS price transparency data confirms a 2-3x billing differential between independent centers and hospital outpatient departments.
PSA Test prices without insurance vs. 2026 Medicare rates| Site of Service | Range Without Insurance | 2026 Medicare Rate |
|---|
| Direct-to-consumer lab (Quest, LabCorp, online order) | $30 to $80 | $22 (CLFS 2026, no patient cost-sharing) |
| Physician office (bundled with visit and interpretation) | $100 to $250 | $22 lab + office visit rate (no patient cost-sharing for lab) |
| Hospital outpatient department | $200 to $350 | $85 (OPPS APC 2026, no patient cost-sharing for screening) |
| Federally Qualified Health Center (FQHC, sliding scale) | $0 to $60 | Covered under FQHC Medicare rate |
2026 Medicare Clinical Lab Fee Schedule (CLFS) rate for G0103 is approximately $22, payable with no patient cost-sharing. Hospital outpatient (OPPS) rate is approximately $85 for the facility component when the test is ordered in that setting. Without-insurance ranges reflect FAIR Health Consumer, CMS price transparency data, and direct-to-consumer lab published prices. Physician professional fee for interpretation billed separately if applicable.
Source: CMS 2026 Clinical Lab Fee Schedule, CMS 2026 Hospital OPPS, FAIR Health Consumer 2026, CMS Hospital Price Transparency
Why the Same Procedure Is So Much More at a Hospital
The 2026 site-of-service pricing difference for a PSA test is driven by whether a hospital facility fee is attached to the order. A physician office or independent lab bills only for the lab processing and, if applicable, an office visit. A hospital outpatient department bills an additional facility fee under the Hospital Outpatient Prospective Payment System (OPPS), which can add $100 to $200 or more to the total. According to CMS price transparency data, the hospital outpatient cash price for a PSA test commonly runs two to three times the independent lab cash price for the same blood draw and analysis. Patients who go to a hospital-affiliated physician office may unknowingly trigger hospital outpatient billing even for a routine lab order.
The practical approach for uninsured or cash-pay patients is to use a direct-to-consumer lab service, which skips the facility fee entirely. National networks such as Quest Diagnostics and LabCorp offer self-pay PSA tests that are ordered online and drawn at a patient service center. Many such services publish the price online before you order. If a physician visit is needed to interpret an elevated PSA or decide on follow-up, that visit can be scheduled separately. The chargemaster price at hospital outpatient labs can be substantially higher than direct-to-consumer pricing, but most hospitals publish a self-pay or uninsured discount policy (typically 20 to 60 percent off chargemaster) and some apply the discount automatically when the patient identifies as uninsured.
PSA Test cost by type and order pathway in 2026
PSA test pricing varies by the type of test ordered (total PSA alone vs. free-to-total ratio or velocity panel) and the pathway used to order it. A basic total PSA is the standard screening test; more complex panels add cost. Understanding which type of PSA test is ordered and how the order is routed determines most of the price variation.
Typical cost by variant| Test Type | What it measures | Cash price range (2026) | Medicare coverage |
|---|
| Total PSA (screening, G0103) | Total PSA level in blood | $30 to $80 (lab only) | $0 to patient annually for men 50+ |
| Free PSA (percent free PSA) | Ratio of free to total PSA | $40 to $120 | Covered if medically necessary |
| PSA velocity / serial panel | PSA change rate over time | $60 to $180 | Covered if medically necessary |
| 4Kscore or Prostate Health Index (PHI) | Advanced multi-marker risk assessment | $150 to $400 | Coverage varies by plan; not universally covered |
HCPCS G0103 covers the Medicare annual prostate cancer screening PSA test at no patient cost-sharing. Diagnostic PSA tests (ordered to evaluate symptoms or monitor known disease) use CPT codes and are subject to normal Part B cost-sharing (20% coinsurance after the 2026 $283 deductible). Advanced biomarker tests (4Kscore, PHI) are not covered under the screening benefit and require separate medical necessity review by payers.
Source: CMS 2026 Clinical Lab Fee Schedule, AUA/SUO 2026 Guideline, FAIR Health Consumer 2026
What Medicare Pays for PSA Test
Original Medicare covers one prostate cancer screening PSA test per year for men who have reached age 50, billed under HCPCS G0103 and paid under the Medicare Clinical Lab Fee Schedule (CLFS). For this covered annual screening, the patient pays $0: no Part B deductible applies and no coinsurance is charged. The 2026 CLFS rate for G0103 is approximately $22 (paid directly to the laboratory). When the PSA test is ordered in a hospital outpatient department, an additional OPPS facility rate of approximately $85 applies, though the patient cost-sharing remains $0 for the preventive screening component. Medicare Part B also covers an annual digital rectal exam (DRE) for men age 50 and over in the same visit at $0 cost-sharing. If a second PSA test is ordered within the same 12-month period, Medicare will deny the second claim unless medical necessity is documented.
Medicare Advantage plans must cover all services that Original Medicare covers, including the annual PSA screening at $0 cost-sharing. Many Medicare Advantage plans cover additional prostate cancer screening benefits or lower-cost follow-up services. Patients should review the plan's Summary of Benefits to confirm PSA and follow-up imaging coverage. Medigap supplemental policies cover the 20% coinsurance that applies to diagnostic PSA tests and follow-up services that are not classified as preventive, such as a urology consultation triggered by an elevated PSA result. A diagnostic PSA test ordered to evaluate symptoms or monitor a known prostate condition is not covered under the G0103 preventive benefit and is instead subject to the standard 2026 Part B cost-sharing: 20% coinsurance after the $283 annual Part B deductible. Commercial ACA-compliant plan coverage varies: the USPSTF Grade C rating means ACA plans are not required to cover PSA screening at 100%, though many include it as a covered benefit with varying cost-sharing. Patients with a high-deductible health plan may owe the full lab and visit cost until the deductible is met.
Under the No Surprises Act, effective January 1, 2022, any patient who is uninsured or choosing to pay out of pocket has the right to a written Good Faith Estimate from the ordering provider before the PSA test is performed. For a PSA test scheduled at least 10 business days out, the provider must furnish the Good Faith Estimate at least 3 business days before the service. For appointments scheduled 3 to 9 business days out, the estimate arrives at least 1 business day before service. The estimate must itemize expected charges, including the lab processing fee, the blood draw fee, any physician interpretation charge, and any facility fee if the order is placed in a hospital-affiliated setting. Federal consumer guidance is available at cms.gov/nosurprisesact.
To request a Good Faith Estimate for a PSA test in 2026, follow these steps: (1) Contact the lab, physician office, or hospital outpatient department and identify yourself as self-pay or uninsured. (2) Ask for a written Good Faith Estimate that includes the lab processing fee, the phlebotomy (blood draw) charge, the physician interpretation fee if applicable, any facility fee if the order is hospital-based, and the diagnosis code used to order the test. (3) Provide your ZIP code so the estimate reflects local pricing. (4) Confirm the delivery timing: 3 business days before service if the test is scheduled 10 or more business days out, 1 business day before service if scheduled 3 to 9 business days out. (5) Keep the written Good Faith Estimate. If the final bill exceeds the estimate by $400 or more, you have 120 days from the bill date to file a patient-provider dispute resolution claim at cms.gov/nosurprisesact.
A Good Faith Estimate for a PSA test is not a guaranteed final bill. Common reasons the actual charges exceed the estimate include: an additional physician consultation triggered by an unexpected result at the same visit, a specimen re-run required by the lab, an unexpected upgrade from total PSA to a free-to-total ratio panel, facility fee added for a blood draw performed at a hospital-based phlebotomy station, and transportation or processing fees for a specimen requiring special handling. If the final bill exceeds the Good Faith Estimate by $400 or more, the patient has 120 days from the bill date to file a patient-provider dispute resolution claim at the federal portal. This right applies to all uninsured and self-pay patients regardless of the provider type.
What Factors Affect Cost
- Site of service: a direct-to-consumer lab order costs $30 to $80 in 2026 for the lab component only. The same PSA test ordered in a hospital outpatient department can reach $200 to $350 due to the hospital facility fee added under the OPPS billing model. Choosing an independent lab is the single most effective cost-reduction lever for uninsured patients.
- Independent lab cash-pay programs: Quest Diagnostics and LabCorp both offer direct-to-consumer PSA test ordering online with published cash prices of $30 to $75 in 2026. Direct-to-consumer lab networks (including services like Ulta Lab Tests and RequestATest) bundle the lab fee and offer prepaid pricing, typically 40 to 70 percent below a hospital outpatient rate for the same test.
- Hospital chargemaster discount ask: if you must use a hospital-affiliated lab, ask for the self-pay or uninsured discount before the test. Most hospitals publish a self-pay discount policy of 20 to 60 percent off the chargemaster price. Some hospitals apply the discount automatically when the patient identifies as uninsured; others require submitting a written request. The chargemaster is the list price almost no one pays in full.
- Sliding-scale Federally Qualified Health Centers (FQHCs): FQHCs serve patients on sliding-scale fees based on household size and income. For patients at or below 100% of the federal poverty level ($15,650 for a household of one in 2026), the PSA test and associated visit can cost as little as $0 at a participating FQHC. Patients can find the nearest FQHC through the HRSA health center finder at findahealthcenter.hrsa.gov.
- Insurance status and plan type: on an ACA-compliant plan, coverage depends on whether the plan includes PSA screening as a covered preventive benefit (the USPSTF Grade C means coverage at 100% is not mandated). Patients on high-deductible health plans pay the full lab and visit cost until their deductible is met. Always call the plan before scheduling to confirm whether PSA screening is covered and at what cost-sharing tier.
- Test type ordered: a basic total PSA costs $30 to $80. A free-to-total PSA ratio (used to refine results when total PSA is borderline) adds $40 to $120. Advanced biomarker panels such as the 4Kscore or Prostate Health Index (PHI) test, used to determine whether a biopsy is warranted, range from $150 to $400 and are not always covered by insurance without prior authorization.
- Geographic region: PSA test prices are generally more uniform nationally than imaging procedures because labs operate on standardized fee schedules. However, hospital outpatient rates in urban Northeast and California markets can run 15 to 30 percent above the national average. Direct-to-consumer lab pricing through national chains is more geographically consistent.
Common PSA Test Billing Errors
PSA test billing errors are less common than with surgical procedures, but several patterns regularly inflate patient bills. Check for these before paying:
- Screening PSA (G0103) billed as a diagnostic PSA under a CPT code, triggering the 20% coinsurance and $283 Part B deductible that do not apply to the annual preventive screening benefit. Ask for the billing code used and confirm it matches G0103 for Medicare annual screening.
- Hospital outpatient facility fee charged for a blood draw that occurred at a physician office affiliated with but separately licensed from the hospital. If you went to a private urology practice, you should not have a hospital facility fee on the bill.
- Duplicate billing: a single PSA draw billed twice (once by the ordering physician and once by an independent lab subcontracted to process the specimen). Review the itemized explanation of benefits for two separate PSA line items for the same date of service.
- Free PSA or PSA ratio billed as part of the annual screening benefit (G0103) when it was actually a separately ordered reflex test. The G0103 benefit covers only the total PSA screening; additional panels are separate claims and may carry cost-sharing.
- Annual frequency limit violation: Medicare covers only one PSA screening per 12 months. If a PSA test is ordered again within 12 months without documented diagnostic medical necessity, it will be denied. Patients sometimes receive unexpected bills for a second PSA billed as diagnostic rather than screening to work around the frequency limit.
Frequently Asked Questions
How much does a PSA test cost without insurance in 2026?
Without insurance in 2026, a PSA test costs $30 to $80 for the lab component alone through a direct-to-consumer service such as Quest Diagnostics or LabCorp. When a physician office visit and interpretation are bundled, total cash prices typically run $100 to $250. A PSA test ordered in a hospital outpatient department can reach $200 to $350 or more due to the added hospital facility fee. The most cost-effective approach for an uninsured patient is to use a direct-to-consumer lab service, order online, and schedule a separate follow-up visit only if the result requires interpretation.
What does Medicare pay for a PSA test in 2026?
Original Medicare covers one annual prostate cancer screening PSA test (HCPCS G0103) for men age 50 and older at $0 cost to the patient. No Part B deductible applies and no coinsurance is charged. The 2026 Medicare Clinical Lab Fee Schedule (CLFS) rate for G0103 is approximately $22, paid directly to the lab. Medicare Advantage plans must cover the same annual screening at $0. A diagnostic PSA test ordered to evaluate symptoms uses a different billing code and is subject to the standard 20% coinsurance after the 2026 Part B deductible of $283. Medigap covers that 20% coinsurance for diagnostic PSA claims.
How do I request a Good Faith Estimate for a PSA test?
Under the No Surprises Act, any uninsured or self-pay patient has the right to a written Good Faith Estimate before a PSA test. To request one: (1) Call the lab, physician office, or hospital and identify yourself as self-pay or uninsured. (2) Ask for a written Good Faith Estimate itemizing the lab fee, blood draw charge, interpretation fee, and any facility fee. (3) Provide your ZIP code. (4) Confirm the timing: 3 business days before service if scheduled 10 or more business days out, 1 business day before service if scheduled 3 to 9 business days out. If your final bill is $400 or more above the estimate, you can file a dispute at cms.gov/nosurprisesact within 120 days.
What is the No Surprises Act and does it apply to a PSA test?
The No Surprises Act took effect January 1, 2022, and protects uninsured and self-pay patients from unexpected medical bills. For a PSA test, the law requires any ordering provider (physician office, hospital, independent lab) to provide a written Good Faith Estimate on request before the service. The estimate must include all anticipated charges: lab processing, phlebotomy, physician interpretation, and any facility fee. If the final bill exceeds the Good Faith Estimate by $400 or more, the patient can file a patient-provider dispute resolution claim within 120 days at the federal portal cms.gov/nosurprisesact. The No Surprises Act does not apply to patients covered by Medicare or Medicaid.
How do I get the lowest cash-pay price for a PSA test in 2026?
The lowest cash price for a PSA test in 2026 comes from ordering through a direct-to-consumer lab network. Quest Diagnostics, LabCorp, and aggregator services such as Ulta Lab Tests and RequestATest publish prices online and let you pay before the blood draw. Published 2026 prices run $30 to $75 for a total PSA. For patients who need a physician to order the test, a telehealth visit plus a direct-to-consumer lab draw is often cheaper than a traditional office visit. If you use a hospital outpatient lab, ask explicitly for the self-pay or uninsured discount: most hospitals discount 20 to 60 percent off the chargemaster price. Get any quoted price in writing as a Good Faith Estimate.
Can I negotiate a PSA test bill after the fact?
Yes. Even after receiving a PSA test bill, you can negotiate. Call the billing department and ask for the self-pay or uninsured discount; typical reductions are 20 to 50 percent for cash-pay-now offers. If the bill includes an unexpected hospital facility fee (which should not appear if the blood draw was in an independent physician office), dispute that charge specifically. If your final bill exceeds the Good Faith Estimate you received by $400 or more, you have 120 days to file a federal patient-provider dispute resolution claim. Non-profit hospitals are required to offer charity care programs; ask about charity care eligibility if your income is below 200 to 300 percent of the federal poverty level.
What is the difference between hospital and independent lab PSA test cost?
The PSA test itself is identical regardless of site, but billing differs substantially. An independent lab or direct-to-consumer service charges $30 to $80 for the lab component alone. A hospital outpatient lab adds a facility fee under the Hospital Outpatient Prospective Payment System, making the total $200 to $350 or more for the same blood draw and analysis. Under the 2026 Medicare OPPS, the hospital facility rate is approximately $85 on top of the $22 CLFS lab rate. Choosing an independent lab rather than a hospital-affiliated lab is the most impactful pricing decision an uninsured PSA test patient can make.
Is a PSA test covered by ACA preventive care at 100%?
Not automatically. The U.S. Preventive Services Task Force (USPSTF) assigns a Grade C recommendation to PSA-based prostate cancer screening for men ages 55 to 69, meaning it involves individualized shared decision-making rather than a universal recommendation. ACA-compliant plans are required to cover only USPSTF Grade A and B services at 100% with no cost-sharing. A Grade C service like the PSA test is not mandated to be covered at 100%, so ACA plans may charge a copay, coinsurance, or apply the deductible. Many plans do cover the PSA test as a preventive benefit, but patients should call their plan to confirm the specific cost-sharing before the appointment. Medicare covers the annual PSA test at $0 with no age limit beyond the 50+ eligibility threshold.
What is the difference between a PSA test and a prostate biopsy?
A PSA test is a simple blood draw that measures the level of prostate-specific antigen in the blood. It is the first-line screening tool and costs $30 to $350 depending on site of service in 2026. A prostate biopsy is an invasive procedure performed when PSA results or other findings suggest possible cancer: a physician inserts a needle into the prostate (usually guided by ultrasound) to collect tissue samples for pathology review. A prostate biopsy costs $1,500 to $6,000 without insurance depending on the biopsy technique, site of service, number of cores, and anesthesia. The biopsy is triggered by an elevated or rising PSA, not ordered at the same time. The two procedures have very different risk profiles, costs, and recovery times.
How often should I get a PSA test?
Screening frequency depends on your age, PSA level, and risk factors. The AUA/SUO 2026 guideline recommends shared decision-making starting at age 40 for average-risk men and earlier for high-risk groups (Black men and those with a first-degree relative diagnosed with prostate cancer before age 65). For men with a PSA below 1.0 ng/mL, the AUA recommends re-screening every 2 to 4 years. For those with PSA between 1.0 and 3.0 ng/mL, re-screening every 1 to 2 years is typical. The USPSTF recommends individualized screening decisions only for men ages 55 to 69 and recommends against routine screening for men 70 and older. Medicare covers one PSA screening per 12 months under HCPCS G0103.
